Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
48
IPSEY Quote, Financials, Valuation and Earnings
Last price:
$47.81
Seasonality move
:
6.02%
Day range:
$47.81 - $47.81
52-week range:
$25.11 - $47.81
Dividend yield:
0.83%
P/E ratio:
32.37x
P/S ratio:
3.83x
P/B ratio:
2.08x
Volume:
18
Avg. volume:
2.3K
1-year change:
66.12%
Market cap:
$15.8B
Revenue:
$4.1B
EPS (TTM):
$1.48
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
IPSEY
Ipsen SA
|
-- | -- | -- | -- | -- |
|
CLLS
Cellectis SA
|
$12.7M | -$0.11 | 24.25% | -56.58% | $7.25 |
|
DBVT
DBV Technologies SA
|
$1.3M | -$0.22 | -- | -86.12% | $40.16 |
|
GNFTF
Genfit SA
|
$33.6M | -- | -- | -- | -- |
|
NICXF
Nicox SA
|
-- | -- | -- | -- | -- |
|
TRGNF
Transgene SA
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
IPSEY
Ipsen SA
|
$47.81 | -- | $15.8B | 32.37x | $0.40 | 0.83% | 3.83x |
|
CLLS
Cellectis SA
|
$4.02 | $7.25 | $404.4M | -- | $0.00 | 0% | 5.00x |
|
DBVT
DBV Technologies SA
|
$21.52 | $40.16 | $1.2B | -- | $0.00 | 0% | -- |
|
GNFTF
Genfit SA
|
$9.00 | -- | $450.3M | 49.25x | $0.00 | 0% | 9.90x |
|
NICXF
Nicox SA
|
$0.30 | -- | $24.3M | -- | $0.00 | 0% | 5.89x |
|
TRGNF
Transgene SA
|
$1.00 | -- | $132.3M | -- | $0.00 | 0% | 1,122.44x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
IPSEY
Ipsen SA
|
15.02% | 0.557 | -- | 1.70x |
|
CLLS
Cellectis SA
|
54.27% | 0.329 | 41.7% | 1.35x |
|
DBVT
DBV Technologies SA
|
23.24% | -3.992 | 5.85% | 1.41x |
|
GNFTF
Genfit SA
|
-- | -0.368 | -- | -- |
|
NICXF
Nicox SA
|
54.24% | 0.454 | 91.41% | 1.21x |
|
TRGNF
Transgene SA
|
-- | 0.532 | -- | 1.42x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
IPSEY
Ipsen SA
|
-- | -- | 9.54% | 11.08% | -- | -- |
|
CLLS
Cellectis SA
|
$30M | $5.9M | -15.69% | -31.08% | 16.76% | -$4M |
|
DBVT
DBV Technologies SA
|
-$4.3M | -$36.9M | -211.46% | -280.59% | -- | -$32.5M |
|
GNFTF
Genfit SA
|
-- | -- | -- | -- | -- | -- |
|
NICXF
Nicox SA
|
-- | -- | -24.01% | -43.13% | -- | -- |
|
TRGNF
Transgene SA
|
-- | -- | -182.92% | -182.92% | -- | -- |
Ipsen SA vs. Competitors
-
Which has Higher Returns IPSEY or CLLS?
Cellectis SA has a net margin of -- compared to Ipsen SA's net margin of 1.68%. Ipsen SA's return on equity of 11.08% beat Cellectis SA's return on equity of -31.08%.
Company Gross Margin Earnings Per Share Invested Capital IPSEYIpsen SA-- -- $5.8B CLLSCellectis SA85.76% $0.01 $219.7M -
What do Analysts Say About IPSEY or CLLS?
Ipsen SA has a consensus price target of --, signalling downside risk potential of --. On the other hand Cellectis SA has an analysts' consensus of $7.25 which suggests that it could grow by 80.35%. Given that Cellectis SA has higher upside potential than Ipsen SA, analysts believe Cellectis SA is more attractive than Ipsen SA.
Company Buy Ratings Hold Ratings Sell Ratings IPSEYIpsen SA0 0 0 CLLSCellectis SA2 2 0 -
Is IPSEY or CLLS More Risky?
Ipsen SA has a beta of 0.499, which suggesting that the stock is 50.123% less volatile than S&P 500. In comparison Cellectis SA has a beta of 2.833, suggesting its more volatile than the S&P 500 by 183.275%.
-
Which is a Better Dividend Stock IPSEY or CLLS?
Ipsen SA has a quarterly dividend of $0.40 per share corresponding to a yield of 0.83%. Cellectis SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ipsen SA pays 22.95% of its earnings as a dividend. Cellectis SA pays out -- of its earnings as a dividend. Ipsen SA's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios IPSEY or CLLS?
Ipsen SA quarterly revenues are --, which are smaller than Cellectis SA quarterly revenues of $35M. Ipsen SA's net income of -- is lower than Cellectis SA's net income of $586.4K. Notably, Ipsen SA's price-to-earnings ratio is 32.37x while Cellectis SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ipsen SA is 3.83x versus 5.00x for Cellectis SA. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IPSEYIpsen SA3.83x 32.37x -- -- CLLSCellectis SA5.00x -- $35M $586.4K
-
Which has Higher Returns IPSEY or DBVT?
DBV Technologies SA has a net margin of -- compared to Ipsen SA's net margin of --. Ipsen SA's return on equity of 11.08% beat DBV Technologies SA's return on equity of -280.59%.
Company Gross Margin Earnings Per Share Invested Capital IPSEYIpsen SA-- -- $5.8B DBVTDBV Technologies SA-- -$1.21 $68.9M -
What do Analysts Say About IPSEY or DBVT?
Ipsen SA has a consensus price target of --, signalling downside risk potential of --. On the other hand DBV Technologies SA has an analysts' consensus of $40.16 which suggests that it could grow by 86.61%. Given that DBV Technologies SA has higher upside potential than Ipsen SA, analysts believe DBV Technologies SA is more attractive than Ipsen SA.
Company Buy Ratings Hold Ratings Sell Ratings IPSEYIpsen SA0 0 0 DBVTDBV Technologies SA4 0 1 -
Is IPSEY or DBVT More Risky?
Ipsen SA has a beta of 0.499, which suggesting that the stock is 50.123% less volatile than S&P 500. In comparison DBV Technologies SA has a beta of -0.978, suggesting its less volatile than the S&P 500 by 197.819%.
-
Which is a Better Dividend Stock IPSEY or DBVT?
Ipsen SA has a quarterly dividend of $0.40 per share corresponding to a yield of 0.83%. DBV Technologies SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ipsen SA pays 22.95% of its earnings as a dividend. DBV Technologies SA pays out -- of its earnings as a dividend. Ipsen SA's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios IPSEY or DBVT?
Ipsen SA quarterly revenues are --, which are smaller than DBV Technologies SA quarterly revenues of --. Ipsen SA's net income of -- is lower than DBV Technologies SA's net income of -$33M. Notably, Ipsen SA's price-to-earnings ratio is 32.37x while DBV Technologies SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ipsen SA is 3.83x versus -- for DBV Technologies SA. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IPSEYIpsen SA3.83x 32.37x -- -- DBVTDBV Technologies SA-- -- -- -$33M
-
Which has Higher Returns IPSEY or GNFTF?
Genfit SA has a net margin of -- compared to Ipsen SA's net margin of --. Ipsen SA's return on equity of 11.08% beat Genfit SA's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital IPSEYIpsen SA-- -- $5.8B GNFTFGenfit SA-- -- -- -
What do Analysts Say About IPSEY or GNFTF?
Ipsen SA has a consensus price target of --, signalling downside risk potential of --. On the other hand Genfit SA has an analysts' consensus of -- which suggests that it could fall by --. Given that Ipsen SA has higher upside potential than Genfit SA, analysts believe Ipsen SA is more attractive than Genfit SA.
Company Buy Ratings Hold Ratings Sell Ratings IPSEYIpsen SA0 0 0 GNFTFGenfit SA0 0 0 -
Is IPSEY or GNFTF More Risky?
Ipsen SA has a beta of 0.499, which suggesting that the stock is 50.123% less volatile than S&P 500. In comparison Genfit SA has a beta of 0.130, suggesting its less volatile than the S&P 500 by 86.956%.
-
Which is a Better Dividend Stock IPSEY or GNFTF?
Ipsen SA has a quarterly dividend of $0.40 per share corresponding to a yield of 0.83%. Genfit SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ipsen SA pays 22.95% of its earnings as a dividend. Genfit SA pays out -- of its earnings as a dividend. Ipsen SA's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios IPSEY or GNFTF?
Ipsen SA quarterly revenues are --, which are smaller than Genfit SA quarterly revenues of --. Ipsen SA's net income of -- is lower than Genfit SA's net income of --. Notably, Ipsen SA's price-to-earnings ratio is 32.37x while Genfit SA's PE ratio is 49.25x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ipsen SA is 3.83x versus 9.90x for Genfit SA. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IPSEYIpsen SA3.83x 32.37x -- -- GNFTFGenfit SA9.90x 49.25x -- --
-
Which has Higher Returns IPSEY or NICXF?
Nicox SA has a net margin of -- compared to Ipsen SA's net margin of --. Ipsen SA's return on equity of 11.08% beat Nicox SA's return on equity of -43.13%.
Company Gross Margin Earnings Per Share Invested Capital IPSEYIpsen SA-- -- $5.8B NICXFNicox SA-- -- $46.8M -
What do Analysts Say About IPSEY or NICXF?
Ipsen SA has a consensus price target of --, signalling downside risk potential of --. On the other hand Nicox SA has an analysts' consensus of -- which suggests that it could fall by --. Given that Ipsen SA has higher upside potential than Nicox SA, analysts believe Ipsen SA is more attractive than Nicox SA.
Company Buy Ratings Hold Ratings Sell Ratings IPSEYIpsen SA0 0 0 NICXFNicox SA0 0 0 -
Is IPSEY or NICXF More Risky?
Ipsen SA has a beta of 0.499, which suggesting that the stock is 50.123% less volatile than S&P 500. In comparison Nicox SA has a beta of -0.043, suggesting its less volatile than the S&P 500 by 104.266%.
-
Which is a Better Dividend Stock IPSEY or NICXF?
Ipsen SA has a quarterly dividend of $0.40 per share corresponding to a yield of 0.83%. Nicox SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ipsen SA pays 22.95% of its earnings as a dividend. Nicox SA pays out -- of its earnings as a dividend. Ipsen SA's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios IPSEY or NICXF?
Ipsen SA quarterly revenues are --, which are smaller than Nicox SA quarterly revenues of --. Ipsen SA's net income of -- is lower than Nicox SA's net income of --. Notably, Ipsen SA's price-to-earnings ratio is 32.37x while Nicox SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ipsen SA is 3.83x versus 5.89x for Nicox SA. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IPSEYIpsen SA3.83x 32.37x -- -- NICXFNicox SA5.89x -- -- --
-
Which has Higher Returns IPSEY or TRGNF?
Transgene SA has a net margin of -- compared to Ipsen SA's net margin of --. Ipsen SA's return on equity of 11.08% beat Transgene SA's return on equity of -182.92%.
Company Gross Margin Earnings Per Share Invested Capital IPSEYIpsen SA-- -- $5.8B TRGNFTransgene SA-- -- -$660.3K -
What do Analysts Say About IPSEY or TRGNF?
Ipsen SA has a consensus price target of --, signalling downside risk potential of --. On the other hand Transgene SA has an analysts' consensus of -- which suggests that it could fall by --. Given that Ipsen SA has higher upside potential than Transgene SA, analysts believe Ipsen SA is more attractive than Transgene SA.
Company Buy Ratings Hold Ratings Sell Ratings IPSEYIpsen SA0 0 0 TRGNFTransgene SA0 0 0 -
Is IPSEY or TRGNF More Risky?
Ipsen SA has a beta of 0.499, which suggesting that the stock is 50.123% less volatile than S&P 500. In comparison Transgene SA has a beta of 42.864, suggesting its more volatile than the S&P 500 by 4186.443%.
-
Which is a Better Dividend Stock IPSEY or TRGNF?
Ipsen SA has a quarterly dividend of $0.40 per share corresponding to a yield of 0.83%. Transgene SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ipsen SA pays 22.95% of its earnings as a dividend. Transgene SA pays out -- of its earnings as a dividend. Ipsen SA's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios IPSEY or TRGNF?
Ipsen SA quarterly revenues are --, which are smaller than Transgene SA quarterly revenues of $105.2K. Ipsen SA's net income of -- is lower than Transgene SA's net income of --. Notably, Ipsen SA's price-to-earnings ratio is 32.37x while Transgene SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ipsen SA is 3.83x versus 1,122.44x for Transgene SA. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IPSEYIpsen SA3.83x 32.37x -- -- TRGNFTransgene SA1,122.44x -- $105.2K --
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
50
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 38x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Sell
37
Is GOOGL Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Buy
59
SEZL alert for Feb 27
Sezzle, Inc. [SEZL] is down 13.92% over the past day.
Buy
83
GCT alert for Feb 27
GigaCloud Technology, Inc. [GCT] is down 5.87% over the past day.
Buy
62
LMAT alert for Feb 27
LeMaitre Vascular, Inc. [LMAT] is down 4.76% over the past day.
